跳至主要内容
临床试验/NCT03131427
NCT03131427招募中不适用

A Nation-wide Hospital-based Registry:China Registry for Genetic / Metabolic Liver Diseases

Beijing Friendship Hospital12 个研究点 分布在 1 个国家目标入组 20,000 人开始时间: 2015年6月13日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
招募中
入组人数
20,000
试验地点
12
主要终点
rate of liver-related events of each disease.

研究概览

简要总结

CR-GMLD registry started on June 13, 2015 to collect cases of genetic/metabolic liver diseases from tertiary or secondary hospitals in mainland China. Demographics, diagnosis, laboratory test results, family history and prescriptions were recorded. Patients' whole blood and serum were collected for genetic testing and future researches. These patients will be followed-up every six to twelve months.

详细描述

This web-based database was launched on June 13, 2015 and consists of tertiary or secondary hospitals with special interest and expertise on managing genetic/metabolic liver diseases patients across mainland China. The main inclusion criteria for this registration are patients who were diagnosed or possibly diagnosed with Wilson's disease, hereditary hemochromatosis, hereditary hyperbilirubinemias, inherited cholestatic liver disease or other genetic/metabolic liver diseases. At the first time of data entry, demographics, medical history, biochemistry and hematology results, radiology reports, diagnosis and treatment information were recorded. Patients' whole blood and serum were collected for molecular genetic testing and future researches. Then the registered patients will receive standard of care and be followed-up every 6 to 12 months. On each visit, biochemical, radiological reports, as well as clinical progress were recorded.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

性别
All
接受健康志愿者

入选标准

  • Patients who were diagnosed or possibly diagnosed with Wilson's disease, hereditary hemochromatosis, hereditary hyperbilirubinemias, inherited cholestatic liver disease or other genetic/metabolic liver diseases.

排除标准

  • Patients who are unable or unwilling to provide informed consent.

研究组 & 干预措施

Wilson's Disease

Patients who were diagnosed or possibly diagnosed with Wilson's disease. The diagnosis can be made or possibly made on the basis of Wilson's disease scoring system proposed by the Working Party at the 8th International Meeting on Wilson's disease, Leipzig 2001.

干预措施: Standard of care (Drug)

Hereditary Hemochromatosis

Hereditary hemochromatosis can be clinically diagnosed if: ① transferrin saturation≥45% and/or elevated ferritin; ② iron overload in liver and/or spleen on magnetic resonance imaging (MRI) of liver or on liver histology; ③ exclude causes of secondary iron overload, such as alcoholic or other chronic liver disease, iron-overloading anemia, and parenteral iron overload.

干预措施: Standard of care (Drug)

Hereditary Hyperbilirubinemias

Hereditary hyperbilirubinemias involve four syndromes: Gilbert, Crigler-Najjar, Dubin-Johnson and Rotor, among which the first two are characterized by unconjugated hyperbilirubinemia and the second two by conjugated hyperbilirubinemia. Diagnosis of hereditary hyperbilirubinemia should exclude other causes of hyperbilirubinemia, such as obstructive bile duct (slerosing cholangitis, calculi, parasites), intrahepatic cholestasis(drugs, hepatitis, immune-mediated, infectious), acute or chronic hepatocellular injury(sepsis, parenteral nutrition, severe blood loss/hypotension, trauma, conjestive heart failure), increased bilirubin production(hemolysis, hematological disease), decreased bilirubin uptake (drugs, portosystemic shunting ), reduced conjugation activity (neonatal, thyroid disease, chronic hepatitis/inflammation, wilson's disease).

干预措施: Standard of care (Drug)

Inherited Cholestatic Liver Disease

Patients who were diagnosed or possibly diagnosed with Inherited cholestatic liver disease, including progressive familial intrahepatic cholestasis(PFIC) and benign recurrent intrahepatic cholestasis(BRIC).

干预措施: Standard of care (Drug)

Other genetic/metabolic liver diseases

Patients who were diagnosed or possibly diagnosed with genetic/metabolic liver diseases except for Wilson's disease, hereditary hemochromatosis, hereditary hyperbilirubinemias or inherited cholestatic liver disease.

干预措施: Standard of care (Drug)

结局指标

主要结局

rate of liver-related events of each disease.

时间窗: 10 years

Rates of cirrhosis, decompensation and hepatocellular carcinoma.

次要结局

  • Genotype profile in Chinese patients of each disease(10 years)
  • Causes of death in Chinese patients of each disease(10 years)
  • Natural history of Chinese patients with each disease of different genotype(10 years)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Jidong Jia

Liver Research Center

Beijing Friendship Hospital

研究点 (12)

Loading locations...

相似试验